Company intelligence / Profile preview

Telormedix

Lugano-Bioggio, Switzerlandventurelab.swiss ↗

Ownership: Private
Development stage: Phase 1

Overview

Lead product TMX-101 was in Phase II clinical trial for the treatment of CIS (carcinoma in situ) in the bladder as of 2013. TMX-302 was being developed for psoriasis treatment with EU funding.

Therapeutic areas: OncologyImmunologyDermatology
Modalities: Small moleculesImmunotherapeutic molecules
Industry: Biotech

Drug pipeline

4 assets

TMX-101

3 more assets in the full pipeline.

Request access →

Partnerships

Research consortium with Biopta, Midatech Biogune, Molecular Profiles, and the University Hospital Zurich (USZ)

Beyond the preview

Go deeper on Telormedix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telormedix.

Explore the full profile